Journal article
Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk
- Abstract:
- Background: Differences between gastrointestinal and cardiovascular effects of traditional NSAID or cyclooxygenase-2 selective inhibitor (coxib) are affected by drug, dose, duration, outcome definition, and patient gastrointestinal and cardiovascular risk factors. We calculated the absolute risk for each effect. Methods: We sought studies with large amounts of information to calculate annualised rates for clearly defined gastrointestinal (complicated upper gastrointestinal perforations, ulcers, or bleeds, but not symptomatic or endoscopic ulcers) and serious cardiovascular outcomes (antiplatelet trial collaborators – APTC – outcome of fatal or nonfatal myocardial infarction or stroke, or vascular death). Results: Meta-analyses and large randomised trials specifically analysing serious gastrointestinal bleeding or cardiovascular events occurring with five different coxibs had appropriate data. In total there were 439 complicated upper gastrointestinal events in 49,006 patient years of exposure and 948 serious cardiovascular events in 99,400 patient years of exposure. Complicated gastrointestinal events occurred less frequently with coxibs than NSAIDs; serious cardiovascular events occurred at approximately equal rates. For each coxib, the reduction in complicated upper gastrointestinal events was numerically greater than any increase in APTC events. In the overall comparison, for every 1000 patients treated for a year with coxib rather than NSAID, there would be eight fewer complicated upper gastrointestinal events, but one more fatal or nonfatal heart attack or stroke. Three coxib-NSAID comparisons had sufficient numbers of events for individual comparisons. For every 1000 patients treated for a year with celecoxib rather than an NSAID there would be 12 fewer upper gastrointestinal complications, and two fewer fatal or nonfatal heart attacks or strokes. For rofecoxib there would be six fewer upper gastrointestinal complications, but three more fatal or nonfatal heart attacks or strokes. For lumiracoxib there would be eight fewer upper gastrointestinal complications, but one more fatal or nonfatal heart attack or stroke. Conclusion: Calculating annualised event rates for gastrointestinal and cardiovascular harm shows that while complicated gastrointestinal events occur more frequently with NSAIDs than coxibs, serious cardiovascular events occur at approximately equal rates. For each coxib, the reduction in complicated upper gastrointestinal events was numerically greater than any increase in APTC events.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, bin, 42.2KB, Terms of use)
-
(Version of record, bin, 45.7KB, Terms of use)
-
(Version of record, bin, 36.8KB, Terms of use)
-
(Version of record, bin, 325.4KB, Terms of use)
-
- Publisher copy:
- 10.1186/1471-2474-8-73
Authors
Pfizer Ltd.
More from this funder
Oxford Pain Research Trust
More from this funder
- Publisher:
- BioMed Central
- Journal:
- BMC Musculoskeletal Disorders More from this journal
- Volume:
- 8
- Publication date:
- 2007-08-01
- Edition:
- Publisher's version
- DOI:
- ISSN:
-
1471-2474
- Language:
-
English
- Keywords:
- Subjects:
- UUID:
-
uuid:b7d3f389-124a-4183-925f-f91228067a03
- Local pid:
-
ora:1803
- Deposit date:
-
2008-03-20
- ARK identifier:
Terms of use
- Copyright holder:
- Moore, R A, Derry, S & McQuay, H J
- Copyright date:
- 2007
- Notes:
- © 2007 Moore et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Citation: Moore, R. A., Derry, S. & McQuay, H. J. (2007). 'Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk', BMC Musculoskeletal Disorders, 8: 73. [Available at http://www.biomedcentral.com/1471-2474/8/73].
If you are the owner of this record, you can report an update to it here: Report update to this record